Results 301 to 310 of about 518,198 (339)

Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study). [PDF]

ESMO Open
de Almeida LFC, Leite LF, Filho VOC, Noronha MM, Cappellaro AP, Gouveia M, da Silva JL, Ernst B, de Melo AC, Tarantino P, Batalini F.   +10 more
europepmc   +1 more source

Supplementary Figure 2 from ¹⁸F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors

Anand Giddabasappa, Ziyue Karen Jiang, Bing Yang, Laigao Chen, Feng Liu, Edward Cabral, Sripad Ram, Britton Boras, Nanni Huser, Cathy C. Zhang, Kavon Noorbehesht, Lisa K. Manzuk, Ravi Visswanathan, Sepideh Mojtahedzadeh, Timothy Affolter, Jason Carmody, Aubrey Nayeon Kang, Matthew D. Petroski, Penny Lai Khamphavong, Todd VanArsdale, Quang‐Dé Nguyen, Kevin Maresca, Stephen G. Dann   +22 more
openalex   +1 more source

Oxygen‐independent expression of HIF‐1α during the cell cycle in hepatocellular carcinoma cells controls essential metabolic pathways under normoxia

The FEBS Journal, EarlyView.
In Huh7 cells, HIF‐1α is essential as it maintains the expression of proteins involved in glycolysis and steroid/cholesterol biosynthesis both under normoxia and hypoxia. On the other hand, in HeLa cells, these pathways are induced by HIF‐1α only under hypoxia.
Ioanna‐Maria Gkotinakou, Christina Arseni, Kreon Koukoulas, Martina Samiotaki, George Panayotou, George Simos, Ilias Mylonis   +6 more
wiley   +1 more source

Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors. [PDF]

Breast Cancer Res
Whi W, Shin J, Kim JY, Ahn HK, Park YH, Ahn JS, Lee H.   +6 more
europepmc   +1 more source

Hypoxia regulates Th17/Treg balance by altering chromatin accessibility and gene expression

The FEBS Journal, EarlyView.
T‐cell differentiation into Th17 or iTreg cells is key to inflammation control. Integrated RNA‐seq and ATAC‐seq analyses reveal that hypoxia induces more extensive gene expression changes in iTreg cells. Elevated levels of Hif1a and Stat3, along with increased accessibility to key transcription factor motifs, may predispose these cells toward ...
Mariana Cázares‐Olivera, Shiyang Song, Sofia Ylinen, Talha Qureshi, Bin Li, Zhi Chen   +5 more
wiley   +1 more source

Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Sharaky M, El Kiki SM, Effat H, Mansour HH.   +3 more
europepmc   +1 more source

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment. [PDF]

World J Gastroenterol
Huang SS, Chen W, Vaishnani DK, Huang LJ, Li JZ, Huang SR, Li YZ, Xie QP.   +7 more
europepmc   +1 more source

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis. [PDF]

NPJ Breast Cancer
Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos L, Molteni E, Lipsyc-Sharf M, Gianni C, Bayou N, Dai CS, Giannarelli D, Bria E, Ma CX, Bardia A, Reduzzi C, Cristofanilli M.   +23 more
europepmc   +1 more source